Germicord7.1%

Umbilical Cord Antisepsis in Newborns (Established Use)

Germicord gel is used for antiseptic cleansing/application to the umbilical cord stump of newborn infants. Community-based trials and a Cochrane systematic review have shown that cleansing the cord with chlorhexidine reduces the incidence of omphalitis (cord infection) and neonatal mortality, particularly in home-birth and low-resource settings with high baseline rates of infection. This is the primary, evidence-supported indication for this specific high-strength (7.1%, delivering approximately 4% free chlorhexidine) formulation.

General Topical Antisepsis (Formulation-Dependent Use)

Depending on the specific licensed product, Germicord may also be used as a topical antiseptic for pre-procedural or surgical skin preparation. This use is formulation- and label-specific and should follow the instructions on the particular product's packaging.

Note: Germicord is for external/topical use only. It is not intended for use on mucous membranes, eyes, ears, or broken/deep wounds.

Each gram of gel contains Chlorhexidine Gluconate [7.1%], equivalent to approximately 4% w/w free chlorhexidine base, in an aqueous gel base suitable for topical application to the umbilical cord stump.

Germicord is a topical antiseptic gel containing chlorhexidine gluconate at a high concentration of 7.1% w/w (equivalent to approximately 4% free chlorhexidine base). Chlorhexidine is a broad-spectrum biguanide antiseptic active against a wide range of gram-positive and gram-negative bacteria. At this specific concentration, Germicord is formulated principally for single or short-course application to the umbilical cord stump of newborn infants to reduce the risk of cord infection (omphalitis) and associated neonatal mortality, a use supported by World Health Organization (WHO) guidance for high-risk and home-birth settings.

Topical antiseptic/disinfectant (biguanide antiseptic); Germicord is classified specifically as an umbilical cord antiseptic at this concentration.

Mechanism of Action

Chlorhexidine Gluconate [7.1%] is a cationic biguanide antiseptic. Its positively charged molecule binds to the negatively charged phospholipids of bacterial cell membranes, disrupting membrane integrity. At lower concentrations this effect is bacteriostatic; at the higher concentration present in Chlorhexidine Gluconate [7.1%], the effect is bactericidal, causing precipitation of intracellular contents and cell death.

Chlorhexidine Gluconate [7.1%] has a broad spectrum of activity against gram-positive and gram-negative bacteria, including many organisms implicated in neonatal omphalitis and sepsis, and has residual antimicrobial activity on skin after application.

For external topical use only. Clean hands before application. Apply a thin layer of Germicord gel to cover the entire umbilical cord stump and the skin at its base using a clean fingertip or applicator, as directed by the physician or per the specific product protocol (single application at birth, or once daily for up to 7 days). Avoid contact with the eyes, ears, mouth, and other mucous membranes. Do not cover the treated area with an occlusive (airtight) dressing unless specifically instructed.

Germicord is applied topically to the umbilical cord and has minimal systemic absorption, so clinically significant systemic drug interactions are not expected. Germicord is chemically incompatible with soaps and other anionic (soap-based) compounds, which can reduce its antiseptic activity; the treated area should not be washed with soap immediately before or after application. Organic material (such as blood or mucus) on the skin can also reduce its antimicrobial effectiveness.

Local application of Germicord is generally well tolerated but may cause:

• Mild local skin irritation, redness, or dryness at the application site
• Contact dermatitis in sensitive individuals
• Rare hypersensitivity reactions, including allergic skin reactions; very rare serious allergic/anaphylactic reactions have been reported with chlorhexidine-containing products
• Chemical skin burns have been reported, predominantly with prolonged or occlusive contact of chlorhexidine-based antiseptics on the very immature, fragile skin of extremely premature infants

Seek medical advice if irritation, blistering, or signs of an allergic reaction occur.

Germicord is intended for topical application to the newborn's umbilical cord and is not a maternal medication for use during pregnancy or lactation in the conventional sense. Systemic absorption through intact newborn skin is minimal. Nonetheless, Germicord should be used only as directed by a physician or midwife, and any topical antiseptic use during pregnancy (e.g., for maternal skin/perineal preparation with a formulation-appropriate product) should be discussed with a physician, who can weigh potential benefit against any theoretical risk.

• For external use only; avoid contact with the eyes, ears, mouth, and mucous membranes. If accidental contact occurs, rinse thoroughly with water.
• Use with caution in extremely premature or very low-birth-weight infants, and on very immature or fragile skin, due to an increased risk of chemical skin burns and greater potential for systemic absorption; follow specific facility or product protocols for such infants.
• Do not apply under an occlusive (airtight) dressing unless specifically directed.
• Discontinue use and seek medical advice if signs of irritation, rash, blistering, or allergic reaction develop.
• Keep away from the eyes; if Germicord is thought to be a product intended for surgical/skin antisepsis, follow the specific licensed indication and instructions for that product, as concentration-specific formulations are not interchangeable.

Topical overdose of Germicord is unlikely to cause systemic toxicity given minimal absorption through intact skin; however, excessive or inappropriate use (e.g., prolonged occlusive contact) may increase the risk of local skin irritation or chemical burns. If Germicord gel is accidentally ingested, or if it comes into contact with the eyes or mucous membranes in significant amounts, rinse/flush the affected area thoroughly with water and seek immediate medical attention or contact a poison control center.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Neonates/Newborns: This is the principal population for which Germicord at this concentration is intended, primarily for umbilical cord care; use per specific birth-setting protocol.

Extremely premature/very low-birth-weight infants: Use with additional caution due to increased risk of chemical skin burns and higher potential systemic absorption through immature skin; specific formulation-appropriate guidance should be followed, and use in this subgroup should be directed by a neonatologist/pediatrician.

Renal/Hepatic impairment: Not applicable in the typical sense, as Germicord at this concentration is used topically on newborns with minimal systemic absorption.

Duration follows the specific protocol prescribed: either a single application of Germicord to the umbilical cord shortly after birth, or once-daily application for up to 7 days after birth (until cord separation), as directed by the physician or newborn care program.

Antiseptics and disinfectants; Biguanide antiseptics; Umbilical cord antiseptics

Chlorhexidine Gluconate [7.1%] is a cationic biguanide that binds to and disrupts negatively charged bacterial cell membranes, causing leakage of cellular contents and bactericidal effect against a broad range of gram-positive and gram-negative organisms.

Germicord is specifically formulated and studied for use in newborn infants for umbilical cord antisepsis, and its use in this population (per approved single-application or 7-day protocols) is supported by clinical trial and WHO-referenced evidence showing reduced omphalitis and neonatal mortality in community settings. Use in extremely premature or very low-birth-weight infants requires additional caution due to a higher risk of chemical skin burns and greater potential systemic absorption through very immature skin; safety and dosing in this specific subgroup should be directed by a neonatologist/pediatrician, as formal safety and efficacy data in extremely premature infants are more limited than in term/near-term newborns.